T-Cell Activation

T-cell activation is the process by which a naive or memory T lymphocyte converts recognition of a specific peptide-MHC complex into proliferation, differentiation, and effector function. The central conceptual advance, formalized by Peter Bretscher and Mel Cohn in 1970 and later refined by Kevin Lafferty and colleagues, is that antigen recognition is not self-certifying. A T cell's TCR cannot, by itself, distinguish a self-peptide displayed on a healthy cell from a foreign peptide displayed during infection — both are just peptide-MHC complexes. The immune system therefore requires a second, independent input before committing to activation. This gives the two-signal model:

Signal 2 is supplied almost exclusively by professional Antigen-Presenting Cells — dendritic cells, macrophages, and B cells — because only these cells upregulate B7 costimulatory molecules, and they do so specifically in response to pattern-recognition-receptor signals from pathogens (a link to innate immunity that makes the whole system "danger-aware" rather than merely "foreignness-aware"). Ordinary tissue cells display peptide-MHC constitutively but never express B7, so autoreactive T cells that encounter self-peptide on a random tissue cell receive Signal 1 without Signal 2 and are functionally neutralized rather than activated. This is a central, non-negotiable checkpoint layered on top of thymic selection: central tolerance removes most self-reactive clones in the thymus, but the two-signal requirement provides a second, peripheral layer of tolerance for the self-reactive T cells that inevitably escape.

Step 1 — Antigen surveillance and initial contact. Naive T cells recirculate through lymph nodes, probing dendritic cell surfaces via transient, low-affinity interactions mediated by adhesion molecules (LFA-1–ICAM-1). Each contact lasts only minutes unless the TCR encounters its cognate peptide-MHC.

Step 2 — TCR triggering. Recognition of peptide-MHC by the αβ TCR, stabilized by the CD4 or CD8 coreceptor binding invariant regions of MHC class II or I respectively, triggers clustering of TCR-CD3 complexes. The coreceptor tail is bound by the Src-family kinase Lck, which is brought into proximity with the CD3 chains' cytoplasmic ITAMs (immunoreceptor tyrosine-based activation motifs).

Step 3 — Proximal kinase cascade. Lck phosphorylates the ITAMs on the CD3γε, CD3δε, and ζζ chains. Phosphorylated ITAMs recruit and activate ZAP-70, a Syk-family kinase, which docks via its tandem SH2 domains onto the doubly phosphorylated ζ-chain ITAMs. Active ZAP-70 phosphorylates the transmembrane scaffold protein LAT (linker for activation of T cells) and the cytosolic adaptor SLP-76.

Step 4 — Signal branching from LAT. Phosphorylated LAT nucleates a multiprotein signalosome that activates three parallel branches:

• PLCγ1 hydrolyzes PIP₂ into IP₃ and diacylglycerol (DAG). IP₃ triggers ER calcium release, raising cytosolic Ca²⁺, which activates calcineurin, a phosphatase that dephosphorylates the transcription factor NFAT, allowing its nuclear translocation.
• DAG activates PKCθ and the Ras-MAPK pathway (Ras→Raf→MEK→ERK), which together drive AP-1 (Fos/Jun) formation and NF-κB activation via PKCθ–CARMA1–Bcl10–MALT1 signaling.
• PI3K, recruited to CD28 and to phosphotyrosines in the TCR complex, generates PIP₃, activating AKT, which promotes metabolic reprogramming, survival (via Bcl-xL), and mTOR activity supporting proliferation.

Step 5 — Costimulation amplifies and gates the response. CD28 engagement by B7.1/B7.2 dramatically lowers the threshold for NF-κB and AKT activation and, critically, stabilizes IL-2 mRNA and boosts IL-2 transcription roughly 100-fold compared to TCR engagement alone. IL-2 acts in an autocrine/paracrine loop through the high-affinity IL-2 receptor (CD25/CD122/CD132) to drive clonal proliferation.

Step 6 — The immunological synapse organizes signaling in space and time. Within minutes of stable TCR engagement, receptors and signaling molecules self-organize into a bullseye pattern at the T cell–APC interface:

• cSMAC (central supramolecular activation cluster): TCR-CD3 complexes, CD28, and PKCθ concentrate here.
• pSMAC (peripheral SMAC): a ring of LFA-1–ICAM-1 adhesion that mechanically stabilizes the contact for hours.
• dSMAC (distal SMAC): actin-rich zone excluding large phosphatases like CD45 from the center, sustaining rather than terminating signaling.

This architecture, first visualized by Michael Dustin and Abraham Kupfer using fluorescence microscopy in the late 1990s, converts a signal that would otherwise last seconds into one sustained for 6–8 hours — long enough to commit the cell to division roughly 24 hours later.

Step 7 — Transcriptional output and clonal expansion. NFAT, NF-κB, and AP-1 cooperatively bind the IL-2 promoter and genes controlling cell-cycle entry (Myc, cyclins). The activated T cell begins dividing roughly every 6 hours, undergoing up to 15–20 rounds of division over a week, expanding a single clone into thousands of effector cells while differentiating into Th1, Th2, Th17, Tfh, or cytotoxic effector subsets depending on the cytokine milieu present during priming.

Step 8 — Negative feedback. As activation proceeds, CTLA-4 is upregulated and outcompetes CD28 for B7 binding with far higher avidity, dampening the signal; PD-1, induced upon sustained stimulation, recruits SHP-2 to dephosphorylate proximal TCR signaling components. These checkpoints prevent runaway activation and are the direct molecular targets of modern cancer immunotherapy.

Bretscher and Cohn's theoretical prediction (1970). Before any molecular mechanism was known, immunologists Peter Bretscher and Melvin Cohn proposed on purely logical grounds that lymphocyte activation must require two discriminatory signals, because a single antigen-recognition signal could not distinguish tolerance-inducing self-antigen from immunogenic foreign antigen. Their "associative recognition" model was a conceptual leap that predated any known costimulatory molecule; it was initially framed for B cells but was later shown to apply, in modified form, to T cells.

Lafferty and Cunningham's transplantation experiments (1975). Kevin Lafferty and Alan Cunningham showed that thyroid or pancreatic islet tissue transplanted between mice of different strains was rejected — but if the tissue was first cultured for several weeks (which killed the passenger leukocytes, i.e., donor dendritic cells, embedded in the tissue) before transplantation, the graft survived far longer without rejection despite still expressing foreign MHC. This showed that MHC recognition (Signal 1) was not sufficient for rejection; something delivered by passenger leukocytes — later identified as costimulatory molecules on donor APCs — was required. This was the first direct experimental demonstration of a "second signal" separable from antigen itself.

Jenkins and Schwartz's anergy experiments (mid-1980s). Mark Jenkins and Ronald Schwartz used chemically fixed antigen-presenting cells (fixation preserves peptide-MHC display but destroys costimulatory function) to present antigen to T-cell clones in vitro. T cells that received antigen from fixed APCs failed to proliferate on subsequent restimulation with fully competent APCs, even though the antigen and TCR were unchanged. This state — termed clonal anergy — could be prevented by adding purified costimulatory signals (or IL-2) during the initial fixed-APC exposure, directly proving that Signal 2 during priming determines whether a T cell is functionally activated or permanently disabled.

Identification of CD28 and B7 (Linsley, June, and colleagues, late 1980s–early 1990s). Peter Linsley, Craig Thompson, and Carl June demonstrated biochemically that antibody-mediated crosslinking of CD28 alone had little effect, but crosslinking CD28 together with the TCR produced a massive (up to 100-fold) increase in IL-2 production compared to TCR engagement alone — and this effect was blocked by CTLA-4-Ig, a soluble fusion protein that sequesters B7 ligands. This experiment both identified CD28–B7 as the physiological costimulatory pair and produced the reagent (CTLA4-Ig, later developed into the drug abatacept) that would go on to treat rheumatoid arthritis and prevent transplant rejection in the clinic — a direct translational line from basic mechanism to therapy.

Dustin and Kupfer's synapse imaging (1998–1999). Using time-lapse confocal microscopy of T cells conjugated to supported lipid bilayers or APCs, Abraham Kupfer's and Michael Dustin's groups visualized the real-time self-assembly of TCR and LFA-1 into the concentric cSMAC/pSMAC pattern, directly confirming that TCR signaling is spatially organized and sustained rather than a brief, unstructured collision — validating a structural prediction with live-cell evidence.

Example 1 — Interpreting a costimulation-blockade experiment. A researcher immunizes three groups of mice with the same protein antigen emulsified in adjuvant, then measures antigen-specific T-cell proliferation (as counts-per-minute, CPM, of tritiated thymidine incorporation) seven days later.

Reasoning: Group A shows robust proliferation — both Signal 1 (antigen-MHC) and Signal 2 (CD28-B7, driven by adjuvant-activated APCs) are present. Groups B and C each block one arm of the CD28–B7 costimulatory pair; proliferation collapses to near-background (Group D) levels even though antigen dose and MHC presentation are identical to Group A. This pattern — antigen present, proliferation absent when costimulation is blocked — is the diagnostic signature of a genuine two-signal requirement, distinguishing it from a simple antigen-dose effect (which would show a graded, not all-or-nothing, drop). Note that residual CPM in B/C above the Group D background (900) reflects a small fraction of memory-like or partially costimulation-independent cells; this is why full checkpoint blockade in the clinic never reduces alloimmune responses to exactly zero.

Example 2 — Clinical reasoning: a kidney transplant recipient on belatacept. Belatacept is a higher-affinity, second-generation CTLA4-Ig fusion protein used clinically to prevent transplant rejection by blocking CD28–B7 costimulation. A transplant patient on belatacept presents six months post-transplant with a viral reactivation (BK polyomavirus) but stable graft function and no rejection episode. Reasoning: Belatacept saturates B7.1/B7.2 on antigen-presenting cells, preventing new naive alloreactive T cells from receiving Signal 2 when they encounter donor peptide-MHC (Signal 1) — this explains the absence of rejection, since newly primed alloreactive clones are driven toward anergy rather than activation. However, this same blockade impairs the priming of new antiviral T-cell responses (since viral antigen presentation also requires CD28 costimulation for naive T-cell activation), which is why belatacept carries a known clinical trade-off: excellent graft protection but increased susceptibility to viral reactivation and, notably, post-transplant lymphoproliferative disease associated with EBV — a direct clinical consequence of a mechanism-level fact (costimulation blockade is antigen-nonspecific and affects protective and pathogenic T-cell priming equally).

Transplantation medicine. CTLA4-Ig fusion proteins (abatacept, belatacept) exploit the two-signal model directly, blocking CD28–B7 engagement to induce donor-specific anergy in alloreactive T cells and reduce reliance on calcineurin inhibitors and their nephrotoxicity.

Cancer immunotherapy. Checkpoint inhibitors targeting CTLA-4 (ipilimumab) and PD-1/PD-L1 (nivolumab, pembrolizumab) work by removing the physiological brakes on T-cell activation described above, unleashing anti-tumor T-cell responses — a therapeutic strategy built entirely on the mechanistic logic of costimulatory and coinhibitory signaling.

Autoimmune and inflammatory disease. Abatacept is used clinically to treat rheumatoid arthritis by dampening costimulation-dependent activation of autoreactive T cells; understanding which self-antigens escape peripheral tolerance (via Signal 1 without Signal 2 failing to induce anergy) informs research into type 1 diabetes, multiple sclerosis, and lupus.

CAR-T cell engineering. Chimeric antigen receptor T-cell therapies for leukemia and lymphoma explicitly build costimulatory domains (CD28 or 4-1BB cytoplasmic tails) directly into the synthetic receptor, because a CAR providing Signal 1 alone produces weak, short-lived T-cell responses — a direct engineering application of the two-signal principle.

Vaccine adjuvant design. Adjuvants work substantially by activating pattern-recognition receptors on dendritic cells, upregulating B7 costimulatory molecules and thereby supplying Signal 2 — explaining why purified antigen alone is a poor immunogen and why adjuvant choice shapes the resulting T-cell response, a concept foreshadowing Immunological Memory and Vaccination.

Ask the tutor: How does the two-signal model change when a T cell is a memory cell rather than naive, and why does that matter for vaccine booster design?